1
|
Russi M, Valeri R, Marson D, Danielli C, Felluga F, Tintaru A, Skoko N, Aulic S, Laurini E, Pricl S. Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer. Eur J Pharm Sci 2023; 180:106311. [PMID: 36273785 DOI: 10.1016/j.ejps.2022.106311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 10/19/2022] [Accepted: 10/19/2022] [Indexed: 11/06/2022]
Abstract
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2 PAMAM head. The process resulted in the formation of well-defined (∼10 nm) core-shell nanomicelles (NMs) with excellent encapsulation efficiency (∼70% for DAB and ∼60% for VEM) and good drug loading capacity (∼27% and ∼24% for DAB and VEM, respectively). Dynamic light scattering (DLS), transmission electron microscopy (TEM), small-angle x-ray scattering (SAXS), nuclear magnetic resonance (NMR), isothermal titration calorimetry (ITC), and molecular simulation (MS) experiments were used, respectively, to determine the size and structure of the empty and drug-loaded nanomicelles (DLNMs), along with the interactions between the NMs and their cargoes. The in vitro release data revealed profiles governed by Fickian diffusion; moreover, for both anticancer molecules, an acidic environment (pH = 5.0) facilitated drug release with respect to physiological pH conditions (pH = 7.4). Finally, both DAB- and VEM-loaded NMs elicited enhanced response with respect to free drug treatments in 4 different melanoma cell lines.
Collapse
Affiliation(s)
- Maria Russi
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS) - DEA, University of Trieste, Piazzale Europa 1, Trieste 34127, Italy
| | - Rachele Valeri
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS) - DEA, University of Trieste, Piazzale Europa 1, Trieste 34127, Italy
| | - Domenico Marson
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS) - DEA, University of Trieste, Piazzale Europa 1, Trieste 34127, Italy
| | - Chiara Danielli
- Department of Chemical and Pharmaceutical Sciences, DSCF, University of Trieste, Via Giorgeri 1, Trieste 34127, Italy
| | - Fulvia Felluga
- Department of Chemical and Pharmaceutical Sciences, DSCF, University of Trieste, Via Giorgeri 1, Trieste 34127, Italy
| | - Aura Tintaru
- Aix Marseille Univ, CNRS - Centre Interdisciplinaire de Nanosciences de Marseille (CINaM) UMR 7325 - Département IMMF - Campus Luminy, 163, Avenue de Luminy, Marseille 13288, France
| | - Natasa Skoko
- Biotechnology Development Unit, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
| | - Suzana Aulic
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS) - DEA, University of Trieste, Piazzale Europa 1, Trieste 34127, Italy; Biotechnology Development Unit, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
| | - Erik Laurini
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS) - DEA, University of Trieste, Piazzale Europa 1, Trieste 34127, Italy.
| | - Sabrina Pricl
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS) - DEA, University of Trieste, Piazzale Europa 1, Trieste 34127, Italy; Department of General Biophysics, University of Łódź, ul. Pomorska 141/143, Łódź 90-236, Poland
| |
Collapse
|
2
|
Han R, Sun Y, Kang C, Sun H, Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. J Drug Target 2016; 25:140-148. [PMID: 27356094 DOI: 10.1080/1061186x.2016.1207649] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Combination cancer therapy has attracted considerable attention due to its enhanced antitumor efficacy and reduced toxicity granted by synergistic effects over monotherapy. The application of nanotechnology is expected to achieve coencapsulation of multiple anticancer agents with enhanced therapeutic efficacy. Herein, a unique nanomicelle based on amphiphilic dendrimer (AmD) consisting of a hydrophilic polyamidoamine dendritic shell and a hydrophobic polylactide core is developed for effectively loading and shuttling 5-fluorouracil (5-Fu) and doxorubicin (Dox). The yielded drug-encapsulated dendritic nanomicelle (5-Fu/Dox-DNM) has a modest average size of 68.6 ± 3.3 nm and shows pH-sensitive drug release manner. The parallel activity of 5-Fu and Dox show synergistic anticancer efficacy. The IC50 value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells was 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively. Furthermore, 5-Fu/Dox-DNM significantly inhibits the progression of tumor growth in the MDA-MB-231 xenograft tumor mice model. In conclusion, we have demonstrated that our AmD-based combination therapeutic system has promising potential to open an avenue for coencapsulation of multiple chemotherapeutic agents to promote superior anticancer effect.
Collapse
Affiliation(s)
- Rui Han
- a Department of Pharmacy , The First People's Hospital of Changzhou , Changzhou , China
| | - Yuan Sun
- b Department of Chemistry and Biochemistry , The Ohio State University , Columbus, OH , USA
| | - Chen Kang
- c Division of Pharmacology, College of Pharmacy , The Ohio State University , Columbus, OH , USA
| | - Huijing Sun
- d Nanjing Haiguang Applied Chemistry Research Institute, Aosaikang Pharmaceutical Co., Ltd , Nanjing , China
| | - Wenguang Wei
- e Department of Acupuncture , The First People's Hospital of Changzhou , Changzhou , China
| |
Collapse
|